Head-to-head evidence
Hemay005 vs PALI-2108
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: PDE4 · full Ulcerative Colitis pipeline
Hemay005
Developed by Tianjin Hemay Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05486104 (registry estimate)
PALI-2108
Developed by Palisade Bio
NCT06663605 · Phase 1 · completed
Most of this study randomized healthy volunteers to PALI-2108 or matching placebo under double-blind conditions, though the ulcerative colitis patient cohort was open-label. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: October 2027 · NCT07845487 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Hemay005's landscape · PALI-2108's landscape